KN0.F Dicot Pharma AB

Healthcare Drug Manufacturers - Specialty & Generic Frankfurt Exchange
0.0130 EUR
Close of Nov 12, 2026
0.0101 0.0463
Market cap
EUR 45.1M
P/E
-
P/B
2.30x
ROE
-33.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is KN0.F undervalued?

Graham number

The Graham number of Dicot Pharma AB cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Dicot Pharma AB fundamental analysis

No fundamental analysis for Dicot Pharma AB yet.

Dicot Pharma AB stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Dicot Pharma AB

Dicot Pharma AB (publ) engages in the development of pharmaceutical products in Sweden. It develops LIB-01 that is in Phase 2a clinical trial for the treatment of erectile dysfunction and under medical discovery for treating premature ejaculation. The company was formerly known as Dicot AB (publ) and changed its name to Dicot Pharma AB (publ) in May 2024. Dicot Pharma AB (publ) was incorporated in 2015 and is based in Uppsala, Sweden.

Full company profile